US 12,233,077 B2
Therapeutic treatment of breast cancer based on c-MAF status
Walter Martin Gregory, Ilkley (GB); Juan Carlos Tercero, Madrid (ES); Robert E. Coleman, Sheffield (GB); and Roger Gomis, Barcelona (ES)
Assigned to INBIOMOTION S.L., Barcelona (ES)
Filed by INBIOMOTION S.L., Barcelona (ES)
Filed on Apr. 11, 2023, as Appl. No. 18/298,807.
Application 18/298,807 is a continuation of application No. 16/766,043, granted, now 11,654,153, previously published as PCT/IB2018/059189, filed on Nov. 21, 2018.
Claims priority of provisional application 62/589,630, filed on Nov. 22, 2017.
Prior Publication US 2024/0000816 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/675 (2006.01); A61K 31/663 (2006.01); A61K 45/06 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01); C12Q 1/6886 (2018.01)
CPC A61K 31/675 (2013.01) [A61K 31/663 (2013.01); A61K 45/06 (2013.01); A61P 35/04 (2018.01); C07K 16/2875 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/158 (2013.01)] 22 Claims
 
1. A method for the treatment of a subject having breast cancer, comprising administering to the subject alendronate at a dose of from about 50 mg to about 100 mg, administering risedronate at a dose of from about 20 mg to about 50 mg, or administering ibandronate at a dose from about 100 mg to about 200 mg, wherein the subject has been identified as having a not increased c-MAF gene expression level, copy number, amplification, or gain in a tumor sample compared to a reference value.